Last reviewed · How we verify
NCT06824870
Exploratory Study Evaluating the Effects of Dermo-cosmetic RV5026B Applied for 2 Months in Adults With Erythrocouperosis
NA trial testing RV5026B - ET1732 - Period 1 in Erythrocouperose Associated With Pityriasis Folliculorum of the Face in 28 participants. Terminated before completion.
20 February 2025
Quick facts
| Lead sponsor | Pierre Fabre Dermo Cosmetique |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 28 |
| Start date | 20 October 2023 |
| Primary completion | 20 February 2025 |
| Estimated completion | 20 February 2025 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- RV5026B - ET1732 - Period 1
- reference topical product - Period 2 — full drug profile →
- RV5026B - ET1732 - Period 2
Conditions studied
- Erythrocouperose Associated With Pityriasis Folliculorum of the Face — all drugs for Erythrocouperose Associated With Pityriasis Folliculorum of the Face →
Sponsor
Pierre Fabre Dermo Cosmetique — full company profile →
Who can join
Adults 18 to 75, any sex, with Erythrocouperose Associated With Pityriasis Folliculorum of the Face. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This exploratory study aims to evaluate the effects of the test product RV5026B - ET1732 on erythema, as well as on the sensations of discomfort and relief perceived in subjects with erythrocouperose and associated pityriasis folliculorum. We wish to evaluate: * firstly the test product alone in order to quantify the effects on the signs \& symptoms on the entire face, * then the contribution of the test product in addition to a reference topical treatment. The test product RV5026B - ET1732 was developed to: * Reduce redness, even if it has already set in, and help limit its reappearance * Soothe the sensations of heating and discomfort associated
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06824870
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Pierre Fabre Dermo Cosmetique trials
Trials by the same sponsor.
- NCT07014007 — Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks · NA · not yet recruiting
- NCT07166484 — Assessment of the Effect of the Product RV2666C Formula LA2984 Compared to an Untreated Area With an Epidermally Ablated · not yet recruiting
- NCT06983561 — Description of the Population With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments and Needs Regard · recruiting
- NCT07341659 — Efficacy of Cosmetic Product RV3278B-OS0386 in the Maintenance Phase After Oral Isotretinoin Treatment of Adults Subject · NA · active not recruiting
- NCT06800755 — Evaluation of the Efficacy and Tolerance of the Medical Device RL3020-DP0364 in Adult Population With Stable Mild Plaque · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06824870 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pierre Fabre Dermo Cosmetique
- Last refreshed: 8 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06824870.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing